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The purpose of this work was to evaluate the influence of the clinical profile on lamotrigine (LTG) plasma 
concentrations from patients with refractory epileptic seizures. In this cross-sectional study, therapeutic 
monitoring of LTG, and questionnaires with 75 patients with refractory epileptic seizures of a Hospital 
in Ribeirão Preto-SP-Brazil were performed. The multiple linear regression model was used to verify 
association between the LTG plasma concentrations and the independent variables. Covariance analysis 
was used to compare the mean LTG plasma concentration among the co-medication groups. The LTG 
plasma concentration was associated both with the LTG dosage (mg/kg/day) (p=0.0096) and with the use 
of first generation antiepileptic drugs (AED) (p<0.01), being carbamazepine (CBZ) and phenytoin (PHT), 
the AEDs showing the most prominent influence in reducing LTG plasma concentrations. Adverse events, 
adherence to the pharmacological treatment, and epileptic seizures frequency, did not show significant 
correlation with LTG plasma concentration values. The conclusion is that LTG plasma concentration 
is significantly influenced by the LTG dosage and by the concomitant use of a first generation AED. 
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INTRODUCTION
Drug therapy is the first choice for epilepsy treatment 
in the majority of cases. Monotherapy is usually considered 
as the initial strategy, and despite 47% of patients having 
their seizures under control with only one antiepileptic 
drug (AED), 13% will require the association of a second 
AED to suppress the seizure recurrence. Consequently, 
40% of the patients will continue to experience epileptic 
seizures in spite of adequate drug therapy, eventually being 
regarded as patients with refractory epileptic seizures 
(Kwan, Brodie, 2000; 2003).
In this context, lamotrigine (LTG) is an AED widely 
prescribed in association both with first and/or second 
generation AEDs, which favors the possible occurrence 
of drug interactions, since its metabolism is known to be 
influenced by different AEDs (Reinsberger, Dorn, Krämer, 
2008; Johannessen, Landmark, 2010). Regardless of the 
LTG linear pharmacokinetics, its plasma concentration 
values show high inter-individual variability, as commonly 
seen in clinical practice. In addition to factors related to 
pharmacotherapy, there are other clinical, physiological, 
pathological and even demographic factors influencing 
the pharmacokinetic of LTG (Reinsberger, Dorn, Krämer, 
2008; Patsalos et al., 2008).
Although there are results highlighting the existence 
of factors that may influence LTG plasma concentrations, 
such as evidence of intoxication increasing significantly 
with plasma concentrations above the recommended upper 
limit (15 mg/L) (Khinchi et al., 2008), the literature is not 
clear enough regarding the impact of these interferences 
and about the need for LTG therapeutic drug monitoring 
in clinical routine (Perucca, 2000). Therefore, there is the 
need to more deeply investigate the factors associated with 
alterations in LTG plasma concentrations and the effects of 
A. O. Baldoni, P. Freitas-Lima,V. Alexandre, F. I. S. Ferreira, E. Z. Martinez, R. H. C. Queiroz, A. C. Sakamoto, L. R. L. Pereira
Braz. J. Pharm. Sci. 2018;54(2):e00246Page 2 / 8
such alterations specifically in clinical practice, especially 
in Brazilian patients with refractory epileptic seizures, 
who are normally exposed to associations of two or more 
AEDs (Perucca, 2000; Rivas et al., 2008). Thus, the aim 
of the study is to evaluate the association between LTG 
plasma concentration and the clinical profile of patients 
with refractory epileptic seizures.
MATERIAL AND METHODS 
Ethics approval
The protocol was approved by Ethics Committee 
of the Hospital das Clínicas da Faculdade de Medicina 
de Ribeirão Preto – Universidade de São Paulo, Brazil 
(HC-FMRP-USP) under the process number 8791/2010.
Study design and patients
This cross-sectional study was conducted at the 
Hospital das Clínicas da Faculdade de Medicina de 
Ribeirão Preto – Universidade de São Paulo, Brazil 
(HC-FMRP-USP), a tertiary care center. The selection of 
patients was performed from May 2011 until April 2012. 
The sample size was determined by non-probabilistic 
sampling of convenience, through saturation of 
invitations.
Inclusion cri teria were:  ( i)  ≥18 years old; 
(ii) diagnosis of refractory epileptic seizures (persistence 
or worsening of seizures after an attempt of two 
consecutive AEDs properly chosen and adequately used); 
and (iii) current LTG treatment, in mono- or polytherapy, 
for at least ten days in unchanged dosages and intake 
intervals. Exclusion criteria were: (i) pregnant women; 
(ii) patients with clinical or laboratorial evidence of 
liver and/or kidney dysfunctions; (iii) patients using 
LGT for other indications (not epilepsy); (iv) patients 
with cognitive impairment to answer the questionnaires; 
and (v) patients with LTG plasma concentration 
“not detectable”, according to the analytical method 
subsequently described. 
Patients on LTG treatment were identified in the 
hospital electronic records. After signing the written 
informed consent, patients received the following 
instructions about blood sampling: fast for 8 hours prior 
to the sampling; blood samplings occur from 6:30 am 
to 9 am; any medication should be taken only after the 
blood sampling. After this, patients were interviewed 
and lastly, the patients’ medical records were analyzed 
in search of sociodemographic, clinical and laboratorial 
information.
Therapeutic drug monitoring 
The LTG plasma concentrations were determined by 
high performance liquid chromatography with ultraviolet 
detection (HPLC-UV). The analytical method validated 
for the analyses was adapted from Angelis-Stoforidis et 
al. (1999). 
The blood samples were collected in 4 mL tubes 
using heparin, centrifuged and the plasma aliquots were 
stored at -20 °C until analysis (no more than one week 
after the sampling). For analyses, 500 µL of plasma were 
transferred to a glass tube and 25 µL of internal standard 
(5-ethyl-5-p-tolylbarbituric acid) and 1 mL of acetonitrile 
were added to deproteinize the sample. The whole mixture 
was stirred for one minute, centrifuged for five minutes at 
1800 rpm, and 500 µL of the supernatant were collected 
and dried under air flow. N-hexane and the mobile phase, 
consisting of 78% acetate buffer (0.25 M, pH 4.4) with 
22% organic phase (11:1 acetonitrile:isopropanol, v/v), 
were added to the residue, which was stirred for one minute 
and centrifuged for three minutes. The lower phase was 
then injected into the HPLC-UV system, which consisted 
of a LC-10AT pump, an SPD-10A UV-VIS detector set 
at 220 nm and a C-R8A Chromatopac integrator, all 
purchased from Shimadzu (Japan). The column used was 
a LiChroCART® 125-4 Merck column (LiChrospher® 
100, RP-8, 5 µm), coupled with a LiChroCART® 4-4 
Merck pre-column (LiChrospher® 100, RP-8, 5 µm). The 
injection volume was 100 µL, and the mobile phase flow 
was set at 1 mL/min.
The carbamazepine (CBZ) plasma concentrations 
were determined by polarized immunofluorescence.
Independent variables
The demographic variables of interest were: age, 
gender and body weight. Clinical data were obtained 
from primary (questionnaires) and secondary (registries 
in medical records) information sources. The information 
obtained through primary sources were:
- Adverse events to AED, according to the Adverse 
Events Profile Questionnaire (AEP) - validated in 
Brazil (Baker et al., 1997; Martins et al., 2011). The 
total score ranges from 19 to 75 points, with higher 
values corresponding to higher adverse events fre-
quency;
- Quality of life according to the questionnaire Quality 
of Life in Epilepsy-31 (Qolie-31) - validated in Brazil 
(Da Silva et al., 2007). The total score ranges from 
0 to 100 points; the higher the total score, the better 
the quality of life;
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- Drug therapy adherence according to the Morisky-
Green test (Morisky, Green, Levine, 1986). The 
score comprises one point for questions answered 
as “no” and zero points for questions answered 
as “yes”. The total score ranges from zero to four 
points, with higher total values reflecting a better 
adherence to the pharmacotherapy;
- Pharmacoepidemiological profile: the prescribed 
drug therapy. This data was then confirmed in medi-
cal records.
To obtain the frequency of epileptic seizures, 
medical comorbidities, and evidence of alterations of 
the liver and/or kidney functions (alterations on urea, 
creatinine and/or liver transaminases tests), secondary 
sources were used.
Statistical analyses
The AEDs were divided into different “co-
medication groups” based on the presence of an enzyme 
inhibitor (valproate, VPA), or the presence of enzyme 
inducers (CBZ, phenytoin [PHT], phenobarbital [PB] or 
>200 mg/day topiramate [TPM]), or the presence of both 
inhibitor and inducer. A fourth group was composed of 
patients only on LTG monotherapy. Patients in any of these 
four groups could also receive co-medications known not 
to affect the LTG plasma concentrations (benzodiazepines, 
TPM ≤200 mg/day, oxcarbazepine, ethosuximide, 
gabapentin, levetiracetam and/or vigabatrin) (Johannessen, 
Landmark, 2010).
Covariance analysis (ANCOVA) with adjustments 
for gender, age and body weight was used to compare 
the mean LTG plasma concentration values among the 
co-medication groups. The paired comparisons were 
performed using Bonferroni’s correction. Groups with 
a small sample size (n≤2) were not included in the 
comparison because of their lack of representativeness. 
The multiple linear regression model was used to 
verify any possible association between LTG plasma 
concentration and independent variables of interest, 
namely, age, body weight, LTG dosage (mg/kg/day), 
frequency of epileptic seizures, AEP score and adherence. 
This analysis was performed considering all the plasma 
concentrations quantified in this study and was also 
performed separately, considering only the group co-
medicated with enzyme inducers. The small sample 
size of the other therapeutic schemes (monotherapy, 
inhibitors, and inducers + inhibitors) did not allow the 
analysis separated by groups. The dependent variable was 
converted into a base 10 logarithm scale in order to make 
the residues follow normality assumption.
The Fisher exact test was used to analyze the 
association between adherence and LTG plasma 
concentrations. Pearson Correlation was used to analyze 
association between: LTG plasma concentration and CBZ 
plasma concentration, adverse event scores, and quality 
of life. All statistical analyses were performed using 
SAS (version 9.3) and R software (Brazil). The level of 
significance was set at 0.05 for hypothesis testing.
RESULTS
Patients’ sociodemographic and clinical profiles
Among 341 patients in LTG use, 82 accepted the 
invitation to participate in the study, but seven were 
excluded because they were not in steady state or LTG 
was undetectable in plasma. Thus, 75 patients were 
included in study. The majority were adults between 18 
and 60 years old (97%) and men (53%). On average, 
the patients’ body weight was 74 kg, ranging from 48 to 
145 kg (Table I). 
Regarding the daily dosages of LTG, it was observed 
that 52% of the patients used above 300 mg/day, and 500 
mg/day was the highest prevalence of use (21.3%). And 
67% (10/15) of patients using LTG in monotherapy or 
with VPA were using doses higher than 5.0 mg/kg/day. 
On the other hand, 60% (34/57) of the patients in use of 
LTG with enzyme inducers were using LTG dosages (mg/
kg/day) lower than 5.0 mg/kg/day.
Lamotrigine plasma concentrations
The LTG plasma concentration mean value was 
5.4 mg/L, with 29% of the patients presenting plasma 
concentration values below the lower limit of the 
recommended range (2.5–15.0 mg/L) (Patsalos et al., 
2008). On the other hand, four patients (5.3%) presented 
LTG plasma concentration values above the upper limit of 
the reference range, varying between 18.5 and 25.6 mg/L.
The co-medication groups comparisons using 
ANCOVA with adjustments for gender, age and body weight 
revealed a statistically significant difference among the LTG 
plasma concentration values (p<0.01) (Figure 1).
It was also possible to verify the individual influences 
from AEDs on LTG plasma concentrations. As observed 
in Figure 2, the mean LTG plasma concentration value 
quantified in the monotherapy group (9.9 mg/L) was 
significantly different to that quantified in the group of 
patients using PHT (3.4 mg/L) or CBZ (3.7 mg/L). The 
LTG plasma concentrations from these two latter groups 
were, in their turn, significantly different from that 
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corresponding to the group of patients in VPA treatment 
(14.6 mg/L) (Figure 2). 
Association between LTG plasma concentration 
and CBZ plasma concentration [Pearson Correlation: 
r = 00:09, 95% CI (-0.19, 00:35), p = 00:53] was not 
observed.
Adverse events 
Analyzing the adverse events profile from the 73 
patients who answered the AEP, it was found that the 
most prevalent adverse events were associated to the 
central nervous system, such as somnolence, difficulty 
in concentrating, and nervousness and/or agitation. The 
analysis of AEP identified that 33 patients (44%) presented 
a total score ≥45. There was no association between LTG 
plasma concentrations and AEP total scores (p=0.14). 
Quality of life
Regarding the 62 patients who answered the 
questionnaire, the mean of the general score was 63 (SD 
= 8.58). The results of Qolie-31 presented, in general, 
low scores in all domains related to this humanistic 
parameter, with “concern about crisis” [37 (SD = 
28.26)] and “adverse events” [46 (SD = 28.38)] being 
the domains that presented the highest quality of life 
impairment. Quality of life was inversely associated with 
TABLE I - Sociodemographic and clinical features of the patients with refractory epilepsy using lamotrigine at AEDC of HCFMRP-
USP on the period of May/2011 until April/2012 (n=75)
Variable Enzyme Inducer Group
Enzyme Inhibitor 
Group LTG Monotherapy
B Inducer + Inhibitor
Number of patients 57 05 10 03
Adults/ElderlyA 55/02 05/00 10/00 03/00
Male (%) 31 (54%) 03 (60%) 04 (40%) 02 (67%)
Mean age in years (SD) 37.5 (10.6) 31.4 (9.3) 40.2 (14.3) 41.7 (3.2)
Mean body weight in kg (SD) 74.3 (16.9) 68.9 (10.4) 72.8 (23.8) 71.8 (9.5)
ComorbiditiesC (%) 20 (35%) 02 (40%) 05 (50%) 01 (33%)
AAdults: 18-59 years old, elderly: >60 years old. BMonotherapy, in this case, refers to the absence of enzyme inducers or inhibitors. 
CExpressed as total number of patients with at least one comorbidity. SD: standard deviation.
FIGURE 1 - Comparisons among the mean LTG plasma 
concentrations considering the co-medication groups (n=75). 
(IND: inducers; INI: inhibitors; MONO: monotherapy; SD: 
standard deviation). Horizontal lines at the top of the graph 
indicate pairwise significant differences between the groups.
FIGURE 2 - Comparisons among the mean LTG plasma 
concentrations considering the specific therapeutic schemes taken 
by the adult patients with refractory epileptic seizures (n=75). 
(VPA: valproate; CBZ: carbamazepine; PB: phenobarbital; PHT: 
phenytoin; SD: standard deviation). Horizontal lines at the top 
of the graph indicate pairwise significant differences between 
the groups.
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adverse events obtained from the AEP (r=-0.69; p<0.01) 
(Pearson Correlation).
Adherence to pharmacological treatment
The evaluation of adherence to pharmacological 
treatment from the 74 patients who answered the Morisky-
Green test revealed that 45 patients (60%) presented 
some impairment regarding this parameter. The scores 
obtained by this indirect method and the respective values 
of LTG plasma concentrations in each subgroup were not 
significantly associated, according to Fisher’s exact test 
(p=1.00).
Lamotrigine plasma concentrations and clinical 
response 
The performance of the multiple linear regression 
model to assess any possible association between 
LTG plasma concentrations and clinical and/or 
pharmacotherapeutic variables highlighted that only LTG 
dosage (mg/kg/day) was significantly associated with LTG 
plasma concentration values (p=0.0096) (Table II). 
The determination coefficient (R2) of the model 
was 0.22, highlighting a wide dispersion of the dependent 
variable (LTG plasma concentration) based on the 
independent variables (R2 may range from 0 to 1, with 
values closer to 1 corresponding to smaller variability and 
better fit of the tested model) (Table II).
Based on the influence of AED over LTG plasma 
concentrations, a linear regression analysis was conducted 
considering only the enzyme inducers group. The 
results showed that only LTG dosage (mg/kg/day) is 
associated with LTG plasma concentration (p=0.0116). 
The determination coefficient R2 of this model displayed 
a higher value (R2=0.42) when compared to the R2 from 
the overall analysis (without considering co-medication). 
DISCUSSION
Almost one third (29%) of the patients displayed 
LTG plasma concentration values below the lower limit of 
the recommended reference range. This result is probably 
associated with three main factors: non-adherence to 
treatment, the high prevalence of patients in use of LTG 
dosages (mg/kg/day) lower than the recommended (45%) 
and the possibility of drug interactions particularly with the 
enzyme inducer AEDs (Johannessen, Landmark, 2010), 
since 67%, 11% and 8% of the patients were taking CBZ, 
PB and PHT, respectively. In relation to the four patients who 
presented LTG plasma concentrations above the upper limit 
of the recommended reference range, two of them were in 
use of VPA.
The analysis performed considering the different 
co-medication groups (Figure 1) showed a wide variability 
in LTG plasma concentrations, with group mean values 
varying from 2.82 mg/L (SD=1.05) to 14.16 mg/L (8.54) 
when LTG was taken with “inducer + inhibitor” and with 
“inhibitor”, respectively. As observed, the mean LTG 
plasma concentration seen in the “inhibitor group” was 
approximately four-fold higher than in the “inducers 
group”, even with both groups presenting similar LTG 
dosages (mg/kg/day). Similar results were also found by 
Bootsma et al. (2008), Lalic et al. (2009) and Yamamoto 
et al. (2012). These results suggest that there are 
prescriptions that are not being individualized according 
to the co-medications.
Regarding the influence of AED on LTG disposition, 
the differences in plasma concentration values among 
groups are associated to the enzyme induction or inhibition 
TABLE II - Multiple linear regression model of the lamotrigine plasma concentration with refractory epilepsy patients’ clinical and 
sociodemographic variables, treated at AEDC of HCFMRP-USP between May/2011 and April/2012 (n=75) R2= 0.22
Variable Coefficient Standard Error t-value p-value
Intercept 0.15540 0.39969 0.39 0.6995
LTG dosage mg/kg/day (log10) 0.39755 0.14607 2.72 0.0096
Frequency of seizures (log10) 0.00235 0.08324 0.03 0.9776
AEP score 0.00259 0.00523 0.50 0.6230
Age (years) -0.00042 0.00392 -0.11 0.9161
Body weight (kg) -0.00005 0.00290 -0.02 0.9852
Morisky-Green test 0.10199 0.09269 1.10 0.2777
Adverse events on medical record 0.09926 0.10085 0.98 0.3309
AEP: Adverse Events Profile.
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of the main LTG metabolic pathway (UGT1A4) caused 
by first generation AEDs. Carbamazepine, PHT and PB 
also induce CYP1A2, CYP2C9, CYP2C19 and CYP3A4 
activities, as well as the glucuronyl transferases (including 
UGT1A4), while VPA inhibits these enzymes’ activities 
(Perucca, 2005; Johannessen, Landmark, 2010; Brzakovic 
et al., 2012).
Analysis of the mean values of LTG plasma 
concentrations referred to the different individual AED 
groups (Figure 2), and it was observed that PHT and CBZ 
exerted the most prominent influence in decreasing LTG 
plasma concentrations. These results corroborate those 
from Weintraub and colleagues (2005), that revealed an 
increase of 125% and 50% in LTG clearance when it is 
associated with PHT and CBZ, respectively, while VPA 
decreases the LTG clearance in approximately 60% 
(Weintraub et al., 2005). In addition, May, Rambeck and 
Jurgens (1996) highlight that PHT is the most powerful 
AED in terms of decreasing the LTG plasma concentration, 
followed by PB and CBZ.
The present results reinforce the need, in clinical 
practice, to consider both the LTG dosage and co-
medications when interpreting plasma concentrations 
information. Moreover, polytherapy is, in epilepsy 
treatment, a very common and unavoidable situation, 
which makes therapeutic drug monitoring an essential tool 
to manage drug interactions (Lalic et al., 2009). 
Concerning the findings of adverse events, similar 
results were obtained by a study performed in the United 
Kingdom which identified tiredness, memory problems 
and difficulty in concentrating the most prevalent adverse 
events when patients with several types of epilepsy were 
analyzed, on monotherapy and polytherapy (Andrew et al., 
2012). In our sample, 44% of the patients presented total AEP 
total scores ≥ 45 points, which is according to Gilliam et al. 
(2004), a threshold associated with high risks of intoxication, 
and often require some clinical intervention.
The lack of association between LTG plasma 
concentration values and adverse events was also found by 
Bootsma and colleagues (2008). Faced with this evidence 
and the good tolerability of LTG, it is important that further 
studies evaluate and discuss the possibility of increasing 
the upper limit of the plasma concentration reference 
range of LTG, in relation to what is currently advocated 
(15 mg/L) (Patsalos et al., 2008). Morris and colleagues 
(1998) suggest that a range from 3 to 14 mg/L would be 
appropriate in the case of patients with refractory epileptic 
seizures. It is noteworthy however, that concentrations up 
to 20 mg/L are often well tolerated and associated with 
additional efficacy in refractory epilepsy patients (Patsalos 
et al., 2008). Further studies are clearly needed to re-evaluate 
the LTG plasma concentration reference values, especially 
for patients with refractory epileptic seizures, since 
concentrations above the upper recommended limit could 
be more effective in controlling epileptic seizures without 
compromising tolerability.
Among the limitations of the present study, it is 
important to highlight the reduced prevalence of patients 
(n=4) with plasma concentrations above the upper 
reference limit (15 mg/L) (Patsalos et al., 2008) and the 
impossibility to establish association between the adverse 
events and specific AED, because there are no patients 
using monotherapy. To do so, it would be appropriate 
to conduct a study only with patients using LTG in 
monotherapy. 
Regarding the inversely proportional association 
between quality of life and adverse events (r=-0.69; 
p<0.01), it is in accordance with Gilliam et al. (2004) 
and Alexandre-Junior et al. (2011). This finding should 
be considered as a warning to professionals in clinical 
practice, since it is common for clinical and laboratorial 
parameters to overlap psychosocial results during 
therapeutic plan determination.
Besides these two relevant questions on results 
interpretation, it is important to highlight that a 
longitudinal study conducted by Kaminow et al. (2003) 
evaluating the use of LTG in monotherapy and in 
comparison with first generation AEDs, showed that LTG 
presented better results in terms of improving quality of 
life when compared to CBZ, PHT, and VPA (Kaminow 
et al., 2003). Viteri et al. (2010) also confirmed, through 
prospective cohort, that LTG presents a positive impact 
on epilepsy patients’ quality of life, especially in women 
(Viteri et al., 2010). In the present study it is not possible 
to associate the low scores for quality of life with the 
use of LTG.
Regarding the high prevalence (60%) of problems 
related to non-adherence to pharmacotherapy, it can also 
be one of the factors that contribute to the amount of 
patients (29%) that had LTG plasma concentrations below 
the recommended range. High prevalence rates of non-
adherence to AEDs were also found in studies performed 
in Palestine (64%) (Jones et al., 2006) and in the United 
Kingdom (59%) (Sweileh et al., 2011). The adherence test 
used was very important to investigate possible association 
between the indirect method of evaluation of adherence 
(questionnaire) and the direct method (therapeutic 
monitoring). Among the factors that may explain the lack 
of association (Fisher’s exact test: p=1.00) it is important 
to highlight that there are co-medications taken with LTG, 
and possible biases of information during the application 
of the Morisky-Green test. 
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The multiple linear regression model (Table II) 
showed that only LTG dosage (mg/kg/day) is associated 
with LTG plasma concentrations (p=0.0096). This 
association can be explained by the linear pharmacokinetics 
of LTG (Perucca, 1996) and corroborates the findings 
from Krasnigi et al. (2010), who argued in favor of a 
strong association between LTG dosage and its plasma 
concentration values. 
Lastly, it is relevant to emphasize the limitations of 
the present study: the doses of LTG may be affected by 
other classes of drugs (non-AED). However, due to lack of 
reliable medical records, this variable was not considered 
in the analysis. Furthermore, the patients do not use the 
same LTG dosages (mg/kg/day). Another important fact 
is that despite the widespread use of the Morisky-Green 
test in Brazil, this instrument was developed in a different 
context and it did not follow the procedures of cross-cultural 
adaptation from Brazil.
On the other hand however, the article presents 
results that have impacts on practice: i) for patients in use 
of LTG with a first generation AED, dose-adjustment 
by therapeutic drug monitoring is necessary; ii) clinical 
pharmacists and physicians need to monitor the drug 
interactions of LTG to avoid intoxication and/or increase 
of epileptic seizures; and iii) in clinical practice it is 
important that therapeutic drug monitoring of LTG is 
incorporated into the clinical routine of reference centers 
in refractory epilepsy.
CONCLUSIONS
The LTG plasma concentration values were shown 
to be associated with the LTG dosage (mg/kg/day) taken by 
the evaluated patients (p=0.0096), and were significantly 
influenced by first generation AEDs (p<0.01), being PHT 
and CBZ, the AEDs with higher influences on decreasing 
LTG disposition. Thus, the therapeutic monitoring of LTG 
is indicated when in concomitant use with first generation 
AEDs, especially at the beginning of treatment or when 
there is need for the medication dose change.
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